Point72 Asset Management
GLUE icon

Point72 Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Point72 Asset Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-90,419
Closed -$670K – 4000
2025
Q3 		$670K Buy
+90,419
New +$479K ﹤0.01% 1816
2025
Q1 		– Sell
-250
Closed -$1.74K – 2233
2024
Q4 		$1.74K Buy
+250
New +$1.88K ﹤0.01% 2037
2021
Q3 		– Sell
-25,000
Closed -$568K – 1118
2021
Q2 		$568K Buy
+25,000
New +$509K ﹤0.01% 855

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's GLUE Position: Q4 2025 in Review

Point72 Asset Management sold out of Monte Rosa Therapeutics (GLUE) in Q4 2025, closing a stake of 90,419 shares — an estimated $670K sold.

Point72 Asset Management first reported a position in GLUE in Q2 2021 and held it in 3 quarters. The position peaked at $670K in Q3 2025. 161 funds tracked by Wall St. Rank hold GLUE as of Q4 2025.

  • Point72 Asset Management reported no remaining Monte Rosa Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Point72 Asset Management sold 90,419 Monte Rosa Therapeutics shares in Q4 2025, an estimated $670K.
  • Point72 Asset Management first reported a position in Monte Rosa Therapeutics in Q2 2021 and held it in 3 quarters.
  • Point72 Asset Management's Monte Rosa Therapeutics position peaked at $670K in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2025.

Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.